A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT ID: NCT05813288
Last Updated: 2025-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
654 participants
INTERVENTIONAL
2023-03-27
2025-12-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
NCT04046939
A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
NCT06441812
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
NCT01287039
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
NCT00813748
Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals
NCT02958982
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
150 mg BID
Dexpramipexole 150 mg oral tablet taken twice a day
Dexpramipexole Dihydrochloride
Oral administration of dexpramipexole tablet
75 mg BID
Dexpramipexole 75 mg oral tablet taken twice a day
Dexpramipexole Dihydrochloride
Oral administration of dexpramipexole tablet
Placebo
Placebo oral tablet taken twice a day
Placebo
Oral administration of placebo tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexpramipexole Dihydrochloride
Oral administration of dexpramipexole tablet
Placebo
Oral administration of placebo tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female ≥12 years of age at Screening Visit 1.
Asthma-related criteria
3. Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1.
4. Eosinophil count of ≥0.30x10⁹/L at Screening Visit 1. If the initial value is between 0.250x10⁹/L to 0.299x10⁹/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2).
5. Treatment of asthma, participants must satisfy all the below (items a to c):
1. Participants who have received asthma controller medication with medium or high dose inhaled corticosteroids (ICS ≥500 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021) on a regular basis for at least 12 months prior to Screening Visit 1.
2. Documented treatment with a stable dose of either medium or high dose ICS for at least 3 months prior to Visit 1. The ICS may be contained within an ICS/long-acting β2 agonist (LABA) combination product. Daily oral corticosteroids are an allowed concomitant medication; participants on daily oral corticosteroids must be on a stable dose for 3 months before Screening Visit 1.
3. Use of one of more additional daily maintenance asthma controller medications according to standard practice of care is required. Use of a stable dose of any additional asthma controller medications must be documented for at least 3 months prior to Screening Visit 1.
6. Pre-BD FEV₁ ≥40% and \<80% (\<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2.
7. Variable airflow obstruction documented with at least one of the following criteria:
1. Bronchodilator reversibility at Screening Visit 2, as evidenced by ≥12% and ≥200 mL improvement in FEV₁, 15 to 30 minutes following inhalation of 400 µg (four puffs) of albuterol/salbutamol (≥12% and ≥160 mL for ages 12 to 17). Participants who do not meet the bronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening period, at an unscheduled visit at least 7 days prior to baseline.
2. Bronchodilator reversibility, using the criteria above, documented in the past 24 months prior to Screening Visit 1 or during Screening.
3. Peak flow variation of ≥20% over a 2-week period, documented in the past 24 months prior to Screening Visit 1 or during Screening.
4. Airflow variability in clinic FEV₁ ≥20% between two consecutive clinic visits, documented in the past 24 months prior to Screening Visit 1.
5. Airway hyperresponsiveness (provocative concentration causing a 20% fall in FEV₁ of methacholine \<8 mg/mL or other clinically relevant bronchoprovocation testing) documented in the past 24 months prior to Screening Visit 1 or during Screening.
8. ACQ-6 ≥1.5 at Screening Visit 2.
9. Documented history of at least two asthma exacerbations requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral) within the past 12-month period prior to Screening Visit 1.
General medical history
10. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening and Baseline visits.
11. WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit:
1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective Intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive.
* Or
2. Two protocol acceptable methods of contraception in tandem.
Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for ≥12 months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply:
3. Women \<50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range.
4. Women ≥50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
Exclusion Criteria
1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids) at any time from 4 weeks prior to Screening Visit 1.
Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening Visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status.
2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis).
3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1.
Prohibited medications/procedures
4. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long-acting anti-IL-5) in the past 12 months.
5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab.
6. Treatment with pramipexole (Mirapex®) within 30 days of Baseline.
7. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1.
8. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the coming year.
General medical history
9. Weight \<40 kg at Screening Visit 1.
10. Current smoking within 12 months prior to Screening Visit 1 or a smoking history of \>10 pack-years. Smoking includes tobacco, vaping, and/or marijuana use.
11. Known or suspected alcohol or drug abuse
12. Uncontrolled severe hypertension: systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg prior to Baseline Visit despite anti-hypertensive therapy.
13. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to Baseline Visit.
14. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C.
15. A helminth parasitic infection diagnosed within 24 weeks prior Screening Visit 1 that has not been treated with or has failed to respond to standard of care (SoC) therapy.
16. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements.
17. Known or suspected noncompliance with medication.
18. Unwillingness or inability to follow the procedures outlined in the protocol.
Clinical safety labs
19. Absolute neutrophil count \<2.000x10⁹/L at screening at Screening Visit 1 or Screening Visit 2.
20. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m² at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula \[Levey et al, 2009\] for age ≥18 years at screening; using the Bedside Schwartz \[Schwartz and Work, 2009\] eGFR formula for age \<18).
21. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart.
Cardiac safety
22. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction \<25%.
23. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit.
24. History of cardiac arrhythmia within 3 months prior to Baseline Visit that is not controlled by medication or via ablation.
25. History of long QT syndrome.
26. Corrected QT interval by Fridericia (QTcF) interval \>450 ms for males and \>470 ms for females at Screening Visit 2 or QTcF ≥480 ms for participants with bundle branch block.
27. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including heart rate \<45 beats per minute (bpm) or \>100 bpm.
Pregnancy/Lactation
28. Pregnant women or women breastfeeding.
29. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
30. Allergy or hypersensitivity to dexpramipexole or any of its components.
12 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Areteia Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael E. Wechsler, MD
Role: PRINCIPAL_INVESTIGATOR
National Jewish Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site 30001-287
Mobile, Alabama, United States
Research Site 30001-487
Chandler, Arizona, United States
Research Site 30001-462
Peoria, Arizona, United States
Research Site 30001-322
Surprise, Arizona, United States
Research Site 30001-458
Tucson, Arizona, United States
Research Site 30001-010
Little Rock, Arkansas, United States
Research Site 30001-502
Canoga Park, California, United States
Research Site 30001-485
Inglewood, California, United States
Research Site 30001-362
Laguna Niguel, California, United States
Research Site 30001-497
Los Angeles, California, United States
Research Site 30001-500
Northridge, California, United States
Research Site 30001-489
Pasadena, California, United States
Research Site 30001-501
San Diego, California, United States
Research Site 30001-434
San Diego, California, United States
Research Site 30001-484
Santa Monica, California, United States
Research Site 30001-304
Valencia, California, United States
Research Site 30001-305
Valencia, California, United States
Research Site 30001-291
Jacksonville, Florida, United States
Research Site 30001-318
Maitland, Florida, United States
Research Site 30001-311
Miami, Florida, United States
Research Site 30001-288
Miami, Florida, United States
Research Site 30001-310
Miami, Florida, United States
Research Site 30001-329
Miami, Florida, United States
Research Site 30001-082
Miami, Florida, United States
Research Site 30001-301
Naples, Florida, United States
Research Site 30001-348
Ocala, Florida, United States
Research Site 30001-331
Orlando, Florida, United States
Research Site 30001-293
Orlando, Florida, United States
Research Site 30001-312
Pembroke Pines, Florida, United States
Research Site 30001-429
Plantation, Florida, United States
Research Site 30001-319
Viera, Florida, United States
Research Site 30001-452
Dunwoody, Georgia, United States
Research Site 30001-483
East Point, Georgia, United States
Research Site 30001-366
Lilburn, Georgia, United States
Research Site 30001-328
Maywood, Illinois, United States
Research Site 30001-535
Westchester, Illinois, United States
Research Site 30001-347
Louisville, Kentucky, United States
Research Site 30001-437
Alexandria, Louisiana, United States
Research Site 30001-286
Lafayette, Louisiana, United States
Research Site 30001-313
Marrero, Louisiana, United States
Research Site 30001-352
Zachary, Louisiana, United States
Research Site 30001-414
Annapolis, Maryland, United States
Research Site 30001-472
Farmington Hills, Michigan, United States
Research Site 30001-442
Southfield, Michigan, United States
Research Site 30001-372
Warren, Michigan, United States
Research Site 30001-421
Mankato, Minnesota, United States
Research Site 30001-406
Rochester, Minnesota, United States
Research Site 30001-522
North Las Vegas, Nevada, United States
Research Site 30001-363
Edison, New Jersey, United States
Research Site 30001-499
Hamilton, New Jersey, United States
Research Site 30001-474
Massena, New York, United States
Research Site 30001-455
New York, New York, United States
Research Site US-30001-369
New York, New York, United States
Research Site 30001-300
Schenectady, New York, United States
Research Site 30001-398
Charlotte, North Carolina, United States
Research Site 30001-439
Rocky Mount, North Carolina, United States
Research Site 30001-413
Cleveland, Ohio, United States
Research Site 30001-495
Columbus, Ohio, United States
Research Site 30001-327
Philadelphia, Pennsylvania, United States
Research Site 30001-414
Franklin, Tennessee, United States
Research Site 30001-364
Memphis, Tennessee, United States
Research Site 30001-334
Allen, Texas, United States
Research Site 30001-090
Austin, Texas, United States
Research Site 30001-415
Dallas, Texas, United States
Research Site US-30001-418
Frisco, Texas, United States
Research Site 30001-299
Houston, Texas, United States
Research Site 30001-315
Katy, Texas, United States
Research Site 30001-295
McKinney, Texas, United States
Research Site 30001-373
Mesquite, Texas, United States
Research Site 30001-481
Nederland, Texas, United States
Research Site 30001-297
Pearland, Texas, United States
Research Site 30001-238
San Antonio, Texas, United States
Research Site 30001-377
San Antonio, Texas, United States
Research Site 30001-335
Sugar Land, Texas, United States
Research Site 30001-333
Pleasant View, Utah, United States
Research Site 30001-515
West Valley City, Utah, United States
Research Site 30054-035
Buenos Aires, , Argentina
Research Site 30054-031
Buenos Aires, , Argentina
Research Site 30054-048
Buenos Aires, , Argentina
Research Site 30054-045
Buenos Aires, , Argentina
Research Site 30054-026
Buenos Aires, , Argentina
Research Site 30054-049
Buenos Aires, , Argentina
Research Site 30054-050
Buenos Aires, , Argentina
Research Site 30054-044
Buenos Aires, , Argentina
Research Site 30054-012
Buenos Aires, , Argentina
Research Site 30054-021
Buenos Aires, , Argentina
Research Site 30054-034
Buenos Aires, , Argentina
Research Site 30054-015
Buenos Aires, , Argentina
Research Site 30054-024
Buenos Aires, , Argentina
Research Site 30054-008
Buenos Aires, , Argentina
Research Site -30054-043
Buenos Aires, , Argentina
Research Site 30054-054
Concepción del Uruguay, , Argentina
Research Site 30054-051
Córdoba, , Argentina
Research Site 30054-052
Córdoba, , Argentina
Research Site 30054-047
Mendoza, , Argentina
Research Site 30054-010
Mendoza, , Argentina
Research Site 30054-032
Mendoza, , Argentina
Research Site 30054-028
Mendoza, , Argentina
Research Site 30054-042
Santa Fe, , Argentina
Research Site 30043-013
Salzburg, , Austria
Research Site 30043-012
Vienna, , Austria
Research Site 30043-001
Weiz, , Austria
Research Site 30055-036
Curitiba, , Brazil
Research Site 30055-021
Porto Alegre, , Brazil
Research Site 30055-035
Rio de Janeiro, , Brazil
Research Site 30055-025
Salvador, , Brazil
Research Site 30055-025
São Paulo, , Brazil
Research Site 30056-013
Santiago, Providencia, Chile
Research Site 30056-009
Curicó, , Chile
Research Site 30056-007
Santiago, , Chile
Research Site 30056-013
Santiago, , Chile
Research Site 30056-011
Santiago, , Chile
Research Site 30056-010
Santiago, , Chile
Research Site 30056-006
Santiago, , Chile
Research Site 30056-012
Santiago, , Chile
Research Site 30056-005
Temuco, , Chile
Research Site 30056-014
Viña del Mar, , Chile
Research Site 30086-021
Shanghai, , China
Research Site 30385-008
Zadar, , Croatia
Research Site 30385-002
Zagreb, , Croatia
Research Site 30385-007
Zagreb, , Croatia
Research Site 30420-018
Brno, , Czechia
Research Site 30420-012
Brno, , Czechia
Research Site 30420-003
Jindřichův Hradec, , Czechia
Research Site 30420-007
Lovosice, , Czechia
Research Site 30420-014
Olomouc, , Czechia
Research Site 30420-010
Strakonice, , Czechia
Research Site 30420-009
Teplice, , Czechia
Research Site 30033-012
Cholet, , France
Research Site 30033-005
Grenoble, , France
Research Site 30033-013
Libourne, , France
Research Site 30033-014
Lille, , France
Research Site 30033-002
Lyon, , France
Research Site 30033-001
Marseille, , France
Research Site 30033-006
Marseille, , France
Research Site 30033-007
Montpellier, , France
Research Site 30033-003
Paris, , France
Research Site 30033-015
Reims, , France
Research Site 30033-004
Saint-Herblain, , France
Research Site 30033-018
Strasbourg, , France
Research Site 30049-081
Augsburg, , Germany
Research Site 30049-060
Berlin, , Germany
Research Site 30049-005
Berlin, , Germany
Research Site 30049-004
Cottbus, , Germany
Research Site 30049-082
Delitzsch, , Germany
Research Site 30049-059
Frankfurt, , Germany
Research Site 30049-019
Frankfurt, , Germany
Research Site 30049-006
Fürstenwalde, , Germany
Research Site 30049-035
Hanover, , Germany
Research Site 30049-073
Homburg, , Germany
Research Site 30049-061
Leipzig, , Germany
Research Site 30049-056
Leipzig, , Germany
Research Site 30049-038
Magdeburg, , Germany
Research Site 30049-051
Munich, , Germany
Research Site 30049-028
Munich, , Germany
Research Site 30049-029
Witten, , Germany
Research Site 30036-005
Balassagyarmat, , Hungary
Research Site 30036-001
Budapest, , Hungary
Research Site 30036-014
Debrecen, , Hungary
Research Site 30036-017
Edelény, , Hungary
Research Site 30036-013
Gödöllő, , Hungary
Research Site 30036-006
Szeged, , Hungary
Research Site 30036-018
Szigetvár, , Hungary
Research Site 30091-006
Ahmedabad, Gujarat, India
Research Site 30091-010
Ahmedabad, Gujarat, India
Research Site 30091-011
Himmatnagar, Gujarat, India
Research Site 30091-001
Surat, Gujarat, India
Research Site 30091-024
Rohtak, Haryana, India
Research Site 30091-043
Aurangabad, Maharashta, India
Research Site 30091-004
Nagpur, Maharashta, India
Research Site 30091-023
Nagpur, Maharashta, India
Research Site 30091-033
Pune, Maharashta, India
Research Site 30091-018
Jaipur, Rajasthan, India
Research Site 30091-021
Kanpur, , India
Research Site 30972-008
Beersheba, , Israel
Research Site 30972-001
Jerusalem, , Israel
Research Site 30972-009
Kfar Saba, , Israel
Research Site 30972-011
Ramat Gan, , Israel
Research Site 30972-012
Rehovot, , Israel
Research Site 30972-005
Sha‘ar Ha‘Aliya, , Israel
Research Site 30039-004
Bergamo, , Italy
Research Site 30039-012
Ferrara, , Italy
Research Site 30039-020
Genova, , Italy
Research Site 30039-013
Napoli, , Italy
Research Site 30039-002
Padua, , Italy
Research Site 30039-017
Reggio Emilia, , Italy
Research Site 30039-011
Roma, , Italy
Research Site 20081-010
Kanazawa, , Japan
Research Site 30370-016
Kaunas, , Lithuania
Research Site 30370-017
Klaipėda, , Lithuania
Research Site 30370-002
Vilnius, , Lithuania
Research Site 30052-024
Guadalajara, Jalisco, Mexico
Research Site 30052-025
Morelia, Michoacon, Mexico
Research Site 30052-026
Chihuahua City, , Mexico
Research Site 30052-030
Durango, , Mexico
Research Site 30052-033
León, , Mexico
Research Site 30052-028
Mexico City, , Mexico
Research Site 30052-023
Monterrey, , Mexico
Research Site -30051-023
Arequipa, , Peru
Research Site 30051-022
Lima, , Peru
Research Site 30051-026
Lima, , Peru
Research Site 30051-020
Lima, , Peru
Research Site -30051-028
Lima, , Peru
Research Site 30051-017
Lima, , Peru
Research Site 30051-021
Lima, , Peru
Research Site 30787-388
Rio Piedras, , Puerto Rico
Research Site 30001-383
San Juan, , Puerto Rico
Research Site 30787-405
San Juan, , Puerto Rico
Research Site 30001-345
Vega Baja, , Puerto Rico
Research Site 30027-013
Benoni, , South Africa
Research Site 30027-009
Cape Town, , South Africa
Research Site 30027-011
Cape Town, , South Africa
Research Site 30027-012
Cape Town, , South Africa
Research Site 30027-021
Cape Town, , South Africa
Research Site 30027-007
Durban, , South Africa
Research Site 30027-001
Durban, , South Africa
Research Site 30027-014
Durban, , South Africa
Research Site 30027-023
Durban, , South Africa
Research Site 30027-010
Durban, , South Africa
Research Site 30027-030
Johannesburg, , South Africa
Research Site 30027-026
Johannesburg, , South Africa
Research Site 30027-031
Krugersdorp, , South Africa
Research Site 30027-008
KwaZulu, , South Africa
Research Site 30027-032
Plettenberg Bay, , South Africa
Research Site 30027-029
Polokwane, , South Africa
Research Site 30027-004
Pretoria, , South Africa
Research Site 30027-019
Pretoria, , South Africa
Research Site 30027-015
Thabazimbi, , South Africa
Research Site 30027-018
Vereeniging, , South Africa
Research Site 30027-017
Welkom, , South Africa
Research Site 30082-019
Gwangju, , South Korea
Research Site 30082-022
Seoul, , South Korea
Research Site 30082-018
Seoul, , South Korea
Research Site 20082-028
Seoul, , South Korea
Research Site 30082-010
Suwon, , South Korea
Research Site 30082-017
Wŏnju, , South Korea
Research Site 30034-046
A Coruña, , Spain
Research Site 30034-052
A Coruña, , Spain
Research Site 30034-011
Barcelona, , Spain
Research Site 30034-049
Barcelona, , Spain
Research Site 30034-013
Barcelona, , Spain
Research Site 30034-021
Lugo, , Spain
Research Site 30034-053
Madrid, , Spain
Research Site 30034-037
Madrid, , Spain
Research Site 30034-045
Madrid, , Spain
Research Site 30034-050
Santander, , Spain
Research Site 30034-043
Valencia, , Spain
Research Site 30034-041
Vigo, , Spain
Research Site 30886-013
Douliu, , Taiwan
Research Site 30886-004
New Taipei City, , Taiwan
Research Site 30886-006
New Taipei City, , Taiwan
Research Site 30886-005
Taichung, , Taiwan
Research Site 30886-007
Taichung, , Taiwan
Research Site 30886-011
Tainan, , Taiwan
Research Site 30886-010
Taipei, , Taiwan
Research Site 30886-008
Taipei, , Taiwan
Research Site 30886-003
Taipei, , Taiwan
Research Site 30886-009
Taipei, , Taiwan
Research Site 30090-017
Alanya, , Turkey (Türkiye)
Research Site 30090-018
Ankara, , Turkey (Türkiye)
Research Site 30090-021
Ankara, , Turkey (Türkiye)
Research Site 30090-008
Ankara, , Turkey (Türkiye)
Research Site 30090-009
Ankara, , Turkey (Türkiye)
Research Site 30090-029
Antalya, , Turkey (Türkiye)
Research Site 30090-019
Bornova, , Turkey (Türkiye)
Research Site 30090-016
Çanakkale, , Turkey (Türkiye)
Research Site 30090-027
Gaziantep, , Turkey (Türkiye)
Research Site 30030-024
Istanbul, , Turkey (Türkiye)
Research Site 30090-020
Istanbul, , Turkey (Türkiye)
Research Site 30090-026
Istanbul, , Turkey (Türkiye)
Research Site 30090-011
Istanbul, , Turkey (Türkiye)
Research Site 30090-012
Izmir, , Turkey (Türkiye)
Research Site 30090-013
Mersin, , Turkey (Türkiye)
Research Site 30090-010
Nilufer, , Turkey (Türkiye)
Research Site 30090-022
Tekirdağ, , Turkey (Türkiye)
Research Site 30090-002
Yüreğir, , Turkey (Türkiye)
Research Site 30380-002
Chernivtsi, , Ukraine
Research Site 30380-011
Kyiv, , Ukraine
Research Site 30044-027
Glasgow, , United Kingdom
Research Site 30044-059
High Wycombe, , United Kingdom
Research Site 30044-039
Leicester, , United Kingdom
Research Site 30044-025
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-503693-20
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AR-DEX-22-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.